Company Profile

Profile last edited on: 3/16/21      CAGE: 6LMB3      UEI: E1BJRNH2DDG6

Business Identifier: MTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

16730 Calle De Catalina
Pacific Palisades, CA 90272
   (310) 309-9036
Location: Single
Congr. District: 33
County: Los Angeles

Public Profile

AADi, LLC, - also dba as AADI Biosciences - is a clinical stage biopharmaceutical company structured around in-house invented, lead product TARZIFYX™ - sirolimus albumin-bound nanoparticles for injectable suspension, ABI-009 -- mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation and improved efficacy over other mTOR inhibitors in preclinical models. With mTOR as a therapeutic target well recognized in oncology, Aadi is focused on developing the full potential of albumin-bound sirolimus in therapeutic areas and diseases that are driven by mTOR activation and where the mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety or effective targeting to the disease site. These indications include oncology, cardiovascular, CNS, mitochondrial disease and diseases of ageing.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 2 NIH $1,565,974
Project Title: Investigation of a Nanoparticle Albumin-Bound Mtor Inhibitor, Nab-Rapamycin for T

Key People / Management

  Neil Desai -- Founder, CEO and President

  Mitchall Clark -- Regulatory Affairs and Quality Advisor SVP, Regulatory Affairs and Quality Assur

  Berta Grigorian -- VP Clinical Operations

  Madhu Kalaimalai